Overview of current status of total androgen deprivation in metastasized prostate cancer.
Eur Urol
; 24 Suppl 2: 67-71, 1993.
Article
em En
| MEDLINE
| ID: mdl-8262129
ABSTRACT
The incidence and methods available for the diagnosis of metastatic prostate cancer, together with the development and efficacy of various treatments, are discussed. In patients with good prognostic characteristics, maximal androgen deprivation, with blockade of both testicular and adrenal androgens, seems to be the favored approach. Surgical castration, although effective, seems inferior to depot luteinizing hormone-releasing hormone therapy with respect to patients' acceptance and preference. Nonsteroidal antiandrogens, such as flutamide, have advantages over steroidal compounds both in efficacy and side effects. Recent studies have demonstrated that combination therapy may be superior in terms of progression-free survival and overall survival in patients with metastatic prostate cancer.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Orquiectomia
/
Hormônio Liberador de Gonadotropina
/
Antagonistas de Androgênios
Tipo de estudo:
Prognostic_studies
Limite:
Aged
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Eur Urol
Ano de publicação:
1993
Tipo de documento:
Article
País de afiliação:
Holanda